Report cover image

Inactivated Vaccine Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 115 Pages
SKU # APRC20261587

Description

Summary

According to APO Research, The global Inactivated Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Inactivated Vaccine include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia) and etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine.

The Inactivated Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inactivated Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Inactivated Vaccine Segment by Company

Johnson & Johnson(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
GlaxoSmithKline(U.K.)
Serum Institute of India Pvt(India)
Sanofi Pasteur(France)
MedImmune(U.S.)
Emergent BioSolutions(U.S.)
CSL Limited(Australia)
Astellas Pharma(Japan)
Inactivated Vaccine Segment by Type

Children Inactivated Vaccine
Adult Inactivated Vaccine
Inactivated Vaccine Segment by Application

Hospital
Medical Center
Inactivated Vaccine Segment by Application

Hospital
Medical Center
Inactivated Vaccine Segment by Region


North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Inactivated Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

115 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Inactivated Vaccine by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Children Inactivated Vaccine
2.2.3 Adult Inactivated Vaccine
2.3 Inactivated Vaccine by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Medical Center
2.4 Assumptions and Limitations
3 Inactivated Vaccine Breakdown Data by Type
3.1 Global Inactivated Vaccine Historic Market Size by Type (2020-2025)
3.2 Global Inactivated Vaccine Forecasted Market Size by Type (2026-2031)
4 Inactivated Vaccine Breakdown Data by Application
4.1 Global Inactivated Vaccine Historic Market Size by Application (2020-2025)
4.2 Global Inactivated Vaccine Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Inactivated Vaccine Market Perspective (2020-2031)
5.2 Global Inactivated Vaccine Growth Trends by Region
5.2.1 Global Inactivated Vaccine Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Inactivated Vaccine Historic Market Size by Region (2020-2025)
5.2.3 Inactivated Vaccine Forecasted Market Size by Region (2026-2031)
5.3 Inactivated Vaccine Market Dynamics
5.3.1 Inactivated Vaccine Industry Trends
5.3.2 Inactivated Vaccine Market Drivers
5.3.3 Inactivated Vaccine Market Challenges
5.3.4 Inactivated Vaccine Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Inactivated Vaccine Players by Revenue
6.1.1 Global Top Inactivated Vaccine Players by Revenue (2020-2025)
6.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2020-2025)
6.2 Global Inactivated Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Inactivated Vaccine Head Office and Area Served
6.4 Global Inactivated Vaccine Players, Product Type & Application
6.5 Global Inactivated Vaccine Manufacturers Established Date
6.6 Global Inactivated Vaccine Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Inactivated Vaccine Market Size (2020-2031)
7.2 North America Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Inactivated Vaccine Market Size by Country (2020-2025)
7.4 North America Inactivated Vaccine Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Inactivated Vaccine Market Size (2020-2031)
8.2 Europe Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Inactivated Vaccine Market Size by Country (2020-2025)
8.4 Europe Inactivated Vaccine Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Inactivated Vaccine Market Size (2020-2031)
9.2 Asia-Pacific Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Inactivated Vaccine Market Size by Country (2020-2025)
9.4 Asia-Pacific Inactivated Vaccine Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Inactivated Vaccine Market Size (2020-2031)
10.2 South America Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Inactivated Vaccine Market Size by Country (2020-2025)
10.4 South America Inactivated Vaccine Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Inactivated Vaccine Market Size (2020-2031)
11.2 Middle East & Africa Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Inactivated Vaccine Market Size by Country (2020-2025)
11.4 Middle East & Africa Inactivated Vaccine Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Johnson & Johnson(U.S.)
12.1.1 Johnson & Johnson(U.S.) Company Information
12.1.2 Johnson & Johnson(U.S.) Business Overview
12.1.3 Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
12.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
12.1.5 Johnson & Johnson(U.S.) Recent Developments
12.2 Merck & Co(U.S.)
12.2.1 Merck & Co(U.S.) Company Information
12.2.2 Merck & Co(U.S.) Business Overview
12.2.3 Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
12.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
12.2.5 Merck & Co(U.S.) Recent Developments
12.3 Pfizer(U.S.)
12.3.1 Pfizer(U.S.) Company Information
12.3.2 Pfizer(U.S.) Business Overview
12.3.3 Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
12.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
12.3.5 Pfizer(U.S.) Recent Developments
12.4 GlaxoSmithKline(U.K.)
12.4.1 GlaxoSmithKline(U.K.) Company Information
12.4.2 GlaxoSmithKline(U.K.) Business Overview
12.4.3 GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2020-2025)
12.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
12.4.5 GlaxoSmithKline(U.K.) Recent Developments
12.5 Serum Institute of India Pvt(India)
12.5.1 Serum Institute of India Pvt(India) Company Information
12.5.2 Serum Institute of India Pvt(India) Business Overview
12.5.3 Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2020-2025)
12.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
12.5.5 Serum Institute of India Pvt(India) Recent Developments
12.6 Sanofi Pasteur(France)
12.6.1 Sanofi Pasteur(France) Company Information
12.6.2 Sanofi Pasteur(France) Business Overview
12.6.3 Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2020-2025)
12.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
12.6.5 Sanofi Pasteur(France) Recent Developments
12.7 MedImmune(U.S.)
12.7.1 MedImmune(U.S.) Company Information
12.7.2 MedImmune(U.S.) Business Overview
12.7.3 MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
12.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
12.7.5 MedImmune(U.S.) Recent Developments
12.8 Emergent BioSolutions(U.S.)
12.8.1 Emergent BioSolutions(U.S.) Company Information
12.8.2 Emergent BioSolutions(U.S.) Business Overview
12.8.3 Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
12.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
12.8.5 Emergent BioSolutions(U.S.) Recent Developments
12.9 CSL Limited(Australia)
12.9.1 CSL Limited(Australia) Company Information
12.9.2 CSL Limited(Australia) Business Overview
12.9.3 CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2020-2025)
12.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
12.9.5 CSL Limited(Australia) Recent Developments
12.10 Astellas Pharma(Japan)
12.10.1 Astellas Pharma(Japan) Company Information
12.10.2 Astellas Pharma(Japan) Business Overview
12.10.3 Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2020-2025)
12.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
12.10.5 Astellas Pharma(Japan) Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.